Could a diabetes drug protect hearts in dialysis patients?
NCT ID NCT05687058
First seen May 24, 2026 · Last updated May 24, 2026
Summary
This early-phase study tests whether empagliflozin, a drug already approved for diabetes, heart failure, and kidney disease, is safe for people on dialysis. Researchers will give 24 dialysis patients the drug for 3 months and monitor their health, blood, urine, and heart function. The goal is to gather safety data for a future larger trial, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jackson Medicall Mall Dialysis Clinic
Jackson, Mississippi, 39213, United States
-
University of Mississippi Medical Center
Jackson, Mississippi, 39157, United States
Conditions
Explore the condition pages connected to this study.